title: Patient-reported outcomes in metastatic castration-resistant prostate cancer.
abstract: Many novel therapies are available for use in patients with metastatic castration-resistant prostate cancer (mCRPC), some of which convey substantial progression-free survival and overall survival benefits. Delaying disease progression and providing palliation of symptoms are primary therapeutic aims of treating patients with mCRPC; therefore, ensuring that the benefit-to-harm ratios are acceptable to patients, through systematic measurement of patient-reported outcomes (PROs) using validated tools, is vital. In this Perspectives, we appraised the published reports from clinical trials testing treatments of mCRPC over the past 5 years and found that PROs were either not being measured routinely, or if used, were often not reported adequately, thus hampering evaluation of the true effects of many of these treatments on patients' quality of life. Improvements are needed because data collected directly from patients, not just physician-collected safety data and adverse events, are crucial to inform clinical decision-making on treatment options.
authors.affiliation: Sussex Health Outcomes Research &Education in Cancer (SHORE-C), Brighton &Sussex Medical School, University of Sussex, Falmer, East Sussex BN1 9RX, UK.
authors.forename: Lesley
authors.initials: L
authors.lastname: Fallowfield
authors.affiliation: Department of Oncology, University College Hospital, 235 Euston Road, London NW1 2BU, UK.
authors.forename: Heather
authors.initials: H
authors.lastname: Payne
authors.affiliation: Sussex Health Outcomes Research &Education in Cancer (SHORE-C), Brighton &Sussex Medical School, University of Sussex, Falmer, East Sussex BN1 9RX, UK.
authors.forename: Valerie
authors.initials: V
authors.lastname: Jenkins
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy; D010146:Pain / Q000523:psychology; D010166:Palliative Care / Q000379:methods; D000071066:Patient Reported Outcome Measures; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy* / Q000523:psychology; D011788:Quality of Life
chemical_list: D000970:Antineoplastic Agents